DZ3402A1 - Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement - Google Patents

Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement

Info

Publication number
DZ3402A1
DZ3402A1 DZ013402A DZ013402A DZ3402A1 DZ 3402 A1 DZ3402 A1 DZ 3402A1 DZ 013402 A DZ013402 A DZ 013402A DZ 013402 A DZ013402 A DZ 013402A DZ 3402 A1 DZ3402 A1 DZ 3402A1
Authority
DZ
Algeria
Prior art keywords
treatment
cyclopentanoindoles
methods
same
compositions containing
Prior art date
Application number
DZ013402A
Other languages
English (en)
Inventor
Marc Labelle
Claudio Sturino
Bruno Roy
Carl Berthelette
Michael Boyd
Nicolas Lachance
John Scheigetz
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of DZ3402A1 publication Critical patent/DZ3402A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Computer Security & Cryptography (AREA)
  • Quality & Reliability (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ013402A 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement DZ3402A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25

Publications (1)

Publication Number Publication Date
DZ3402A1 true DZ3402A1 (fr) 2002-01-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013402A DZ3402A1 (fr) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement

Country Status (34)

Country Link
US (1) US6410583B1 (fr)
EP (1) EP1305286B1 (fr)
JP (1) JP4119745B2 (fr)
KR (1) KR100746814B1 (fr)
CN (1) CN1214007C (fr)
AT (1) ATE284388T1 (fr)
AU (2) AU7743001A (fr)
BG (1) BG66084B1 (fr)
BR (1) BR0112756A (fr)
CA (1) CA2416867C (fr)
CZ (1) CZ2003236A3 (fr)
DE (1) DE60107687T2 (fr)
DK (1) DK1305286T3 (fr)
DZ (1) DZ3402A1 (fr)
EA (1) EA006765B1 (fr)
EC (1) ECSP034428A (fr)
EE (1) EE05287B1 (fr)
ES (1) ES2231526T3 (fr)
GE (1) GEP20053595B (fr)
HK (1) HK1058934A1 (fr)
HR (1) HRP20021039B1 (fr)
HU (1) HUP0301745A3 (fr)
IL (2) IL153406A0 (fr)
IS (1) IS2170B (fr)
MX (1) MXPA03000710A (fr)
NO (1) NO325011B1 (fr)
NZ (1) NZ523106A (fr)
PL (1) PL207342B1 (fr)
PT (1) PT1305286E (fr)
RS (1) RS50491B (fr)
SK (1) SK287507B6 (fr)
UA (1) UA73787C2 (fr)
WO (1) WO2002008186A2 (fr)
ZA (1) ZA200300554B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1631547A1 (fr) * 2003-05-20 2006-03-08 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2
US20070027171A1 (en) * 2003-06-12 2007-02-01 Lachance Nicolas Cycloalkanepyrrolopyridines as dp receptor antagonists
EP1656141B1 (fr) * 2003-08-07 2010-04-14 MERCK SHARP & DOHME LTD. Procede pour traiter la maladie d'alzheimer et des pathologies liees
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US8039464B2 (en) 2004-07-16 2011-10-18 Proteosys Ag Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US20090054423A1 (en) * 2005-04-13 2009-02-26 Imbriglio Jason E Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
PT2326621T (pt) * 2008-07-23 2016-09-12 Arena Pharm Inc Derivados de ácido 1,2,3,4-tetrahidrociclopenta[b]indol-3-il) acético substituídos úteis no tratamento de distúrbios autoimunes e inflamatórios
EA036955B1 (ru) 2008-08-27 2021-01-19 Арена Фармасьютикалз, Инк. Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
WO2010030360A1 (fr) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. Dérivés 3h-imidazo[4,5-b]pyridin-5-ol utiles dans le traitement de troubles du récepteur gpr81
JP2012503605A (ja) * 2008-09-25 2012-02-09 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体
EP2387405A2 (fr) 2009-01-13 2011-11-23 ProteoSys AG Pirenzépine en tant qu'agent utilisé dans le traitement du cancer
EP2493881A1 (fr) 2009-10-26 2012-09-05 Bayer CropScience AG Nouvelle forme solide de 4-[[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino]furan-2(5h)-one
EP4148045A1 (fr) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Composés intermédiaires pour la préparation de l'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
WO2014066568A1 (fr) 2012-10-24 2014-05-01 Winthrop-University Hospital Biomarqueur non invasif permettant d'identifier des sujets risquant un accouchement avant terme
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EP3582772A1 (fr) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
MX2020002788A (es) 2017-09-13 2020-09-14 Progenity Inc Biomarcadores de preeclampsia y sistemas y metodos relacionados.
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
EP3847158A1 (fr) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Composés utiles dans le traitement de troubles auto-immuns et inflammatoires
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN115260173A (zh) * 2021-04-30 2022-11-01 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3768097D1 (de) 1986-01-23 1991-04-04 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
CN1134411C (zh) * 1995-06-21 2004-01-14 盐野义制药株式会社 双环氨基衍生物及含有此类化合物的前列腺素d2拮抗剂
RU2161617C1 (ru) * 1996-12-13 2001-01-10 Шионоги энд Ко. Лтд. Бензотиофенкарбоксамидные производные, содержащие их антагонисты pgd2, фармацевтическая композиция и лекарственное средство
DE69925270T2 (de) * 1998-06-03 2006-02-23 Shionogi & Co., Ltd. Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Also Published As

Publication number Publication date
ZA200300554B (en) 2004-04-23
PL207342B1 (pl) 2010-12-31
ATE284388T1 (de) 2004-12-15
JP4119745B2 (ja) 2008-07-16
WO2002008186A3 (fr) 2002-03-21
HK1058934A1 (en) 2004-06-11
HUP0301745A3 (en) 2010-03-29
US6410583B1 (en) 2002-06-25
SK287507B6 (sk) 2010-12-07
UA73787C2 (en) 2005-09-15
AU7743001A (en) 2002-02-05
EP1305286A2 (fr) 2003-05-02
HUP0301745A2 (hu) 2003-09-29
JP2004504380A (ja) 2004-02-12
DK1305286T3 (da) 2005-03-14
HRP20021039A2 (en) 2004-10-31
WO2002008186A2 (fr) 2002-01-31
IL153406A0 (en) 2003-07-06
YU97902A (sh) 2006-05-25
BR0112756A (pt) 2003-06-24
CA2416867A1 (fr) 2002-01-31
CA2416867C (fr) 2008-03-25
NO325011B1 (no) 2008-01-14
EA200300171A1 (ru) 2003-06-26
RS50491B (sr) 2010-03-02
EE05287B1 (et) 2010-04-15
EE200300033A (et) 2004-10-15
ECSP034428A (es) 2003-03-10
IS2170B (is) 2006-11-15
ES2231526T3 (es) 2005-05-16
AU2001277430B2 (en) 2006-05-25
PT1305286E (pt) 2005-04-29
EP1305286B1 (fr) 2004-12-08
IS6655A (is) 2002-12-12
BG107438A (bg) 2003-09-30
NO20030374D0 (no) 2003-01-24
CN1443165A (zh) 2003-09-17
SK932003A3 (en) 2003-06-03
NO20030374L (no) 2003-01-24
DE60107687D1 (de) 2005-01-13
KR20030024810A (ko) 2003-03-26
IL153406A (en) 2008-03-20
EA006765B1 (ru) 2006-04-28
CN1214007C (zh) 2005-08-10
NZ523106A (en) 2005-01-28
DE60107687T2 (de) 2005-12-01
GEP20053595B (en) 2005-08-10
BG66084B1 (bg) 2011-03-31
HRP20021039B1 (en) 2011-03-31
PL363168A1 (en) 2004-11-15
MXPA03000710A (es) 2003-06-04
CZ2003236A3 (cs) 2003-05-14
KR100746814B1 (ko) 2007-08-06

Similar Documents

Publication Publication Date Title
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
BR0113286B1 (pt) pirazàis substituÍdos e composiÇço farmacÊutica compreendendo os mesmos.
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
ES2243579T3 (es) Derivados de pirazolopirideno.
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
YU39201A (sh) Upotreba 1-arilpirazola za pripremanje oralnog sredstva za suzbijanje parazita
SE9801494D0 (sv) Novel use
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
SE0002045D0 (sv) New use
MXPA03003466A (es) Derivados de piranosido.
CR20120385A (es) Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)